Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

INTRODUCTION: To evaluate the efficacy of empagliflozin compared to pioglitazone in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM). METHODS: In this prospective randomized, double-blind, placebo-controlled trial, we assigned 106 patients with NAFLD and T2DM to rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chehrehgosha, Haleh, Sohrabi, Masoud Reza, Ismail-Beigi, Faramarz, Malek, Mojtaba, Reza Babaei, Mohammad, Zamani, Farhad, Ajdarkosh, Hossein, Khoonsari, Mahmood, Fallah, Afshin Eshghi, Khamseh, Mohammad E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882235/
https://www.ncbi.nlm.nih.gov/pubmed/33586120
http://dx.doi.org/10.1007/s13300-021-01011-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882235/
https://www.ncbi.nlm.nih.gov/pubmed/33586120
http://dx.doi.org/10.1007/s13300-021-01011-3

Ejemplares similares